Identification of Novel Inhibitors of the SARS Coronavirus Main Protease 3CLpro

Biochemistry

Volumn 43, Issue 17, 2004, Pages 4906-4912

  Bacha, Usman ^a   Barrila, Jennifer ^a   Velazquez Campoy, Adrian ^a   Leavitt, Stephanie A ^a   Freire, Ernesto ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIFFERENTIAL SCANNING CALORIMETRY; ENZYMES; ESCHERICHIA COLI; ORGANIC ACIDS; VIRUSES;

CATALYTIC EFFICIENCY; SEVERE ACUTE RESPIRATORY SYNDROME (SARS);

BIOCHEMISTRY;

PROTEASE 3CL; PROTEINASE; UNCLASSIFIED DRUG;

ARTICLE; ENZYME DENATURATION; ENZYME INHIBITOR INTERACTION; ENZYME STRUCTURE; INHIBITION KINETICS; MOLECULAR DYNAMICS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; SARS CORONAVIRUS;

AMINO ACID SEQUENCE; BINDING SITES; BORONIC ACIDS; CALORIMETRY, DIFFERENTIAL SCANNING; CATALYTIC DOMAIN; CONSERVED SEQUENCE; CORONAVIRUS; ENZYME INHIBITORS; ESCHERICHIA COLI; KINETICS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; MOLECULAR WEIGHT; PROTEIN DENATURATION; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; SARS VIRUS; SEQUENCE HOMOLOGY, AMINO ACID; SERINE; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; TEMPERATURE; THERMODYNAMICS;

CORONAVIRUS; ESCHERICHIA COLI; SARS CORONAVIRUS;

EID: 2142713046     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi0361766     Document Type: Article

References (28)

1. pro) Structure: Basis for design of Anti-SARS Drugs, Science 300, 1763-1767.
2. Kim, J. C., Spence, R. A., Currier, P. F., Lu, X., and Denison, M. R. (1995) Coronavirus protein processing and RNA synthesis is inhibited by the cysteine proteinase inhibitor E64d, Virology 208, 1-8.
3. Ziebuhr, J., Heusipp, G., and Siddell, S. G. (1997) Biosynthesis, purification and characterization of the human coronavirus 229E 3C-like proteinase, J. Virol. 71, 3992-3997.
4. Yang, H., Yang, M., Ding, Y., Liu, Y., Lou, Z., Zhou, Z., Sun, L., Mo, L., Ye, S., Pang, H., Gao, G. F., Anand, K., Bartlam, M., Hilgenfeld, R., and Rao, Z. (2003) The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor, Proc. Natl. Acad. Sci. U.S.A. 100, 13190-13195.
5. Ziebuhr, J., Snijder, E. J., and Gorbalenya, A. (2000) Virus-encoded proteinases and proteolytic processing in the Nidovirales, J. Gen. Virol. 81, 853-879.
6. Anand, K., Palm, G. J., Mesters, J. R., Siddell, S. G., Ziebuhr, J., and Hilgenfeld, R. (2002) Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra α-helical domain, EMBO J. 21, 3213-3224.
7. Fan, K., Wei, P., Feng, Q., Chen, S., Huang, C., Ma, L., Lai, B., Pei, J., Liu, Y., Chen, J., and Lai, L. (2004) Biosynthesis, purification, and substrate specificity of severe acute respiratory syndrome coronavirus 3C-like proteinase, J. Biol. Chem. 279, 1637-1642.
8. Copeland, R. A. (2000) Enzymes: A practical introduction to structure, mechanism and data analysis, 2nd ed., Wiley-VCH, New York.
9. Muzammil, S., Ross, P., and Freire, E. (2003) A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance, Biochemistry 42, 631-638.
10. Nillroth, U., Vrang, L., Markgren, P. O., Hulten, J., Hallberg, A., and Danielson, U. H. (1997) Human immunodeficiency virus type 1 proteinase resistance to symmetric cyclic urea inhibitor analogs, Antimicrob. Agents Chemother. 41, 2383-2388.
11. Velazquez-Campoy, A., Todd, M. J., Vega, S., and Freire, E. (2001) Catalytic Efficiency and Vitality of HIV-1 Proteases from African Viral Subtypes, Proc. Natl. Acad. Sci. U.S.A. 98, 6062-6067.
12. Maschera, B., Darby, G., Palu, G., Wright, L. L., Tisdale, M., Meyers, R., Blair, E. D., and Furfine, E. S. (1996) Human immunodeficiency virus. Mutations in the viral protease that confers resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex, J. Biol. Chem. 271, 33231-33235,
13. Ermolieff, J., Lin, X. L., and Tang, J. (1997) Kinetic properties of saquinavir-resistant mutants of human immunodeficiency virus type I protease and their implications in drug resistance in vivo, Biochemistry 36, 12364-12370.
14. Pazhanisamy, S., Stuver, C. M., Cullinan, A. B., Margolin, N., Rao, B. G., and Livingston, D. J. (1996) Kinetic Characterization of Human Immunodeficiency Virus Type-1 Protease-resistant Variants, J. Biol. Chem. 271, 17979-17985.
15. Feher, A., Weber, I. T., Bagossi, P., Boross, P., Mahalingam, B., Louis, J. M., Copeland, T. D., Torshin, I. Y., Harrison, R. W., and Tozzer, J. (2002) Effect of sequence polymorphism and drug resistance on two HIV-1 Gag processing sites, Eur. J. Biochem. 269, 4114-4120.
16. Patick, A. K., Rose, R., Greytok, J., Bechtold, C. M., Hermsmeier, M. A., Chen, P. T., Barrish, J. C., Zahler, R., Colonno, R. J., and Lin, P. F. (1995) Characterization of a Human-Immunodeficiency-Virus Type-1 Variant with Reduced Sensitivity to an Aminodiol Protease Inhibitor, J. Virol. 69, 2148-2152.
17. Schock, H. B., Garsky, V. M., and Kuo, L. C. (1996) Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials: Compensatory modulations of binding and activity, J. Biol. Chem. 271, 31957-31963.
18. Ridky, T. W., Kikonyogo, A., and Leis, J. (1998) Drug-resistant HIV-1 proteases identify enzyme residues important for substrate selection and catalytic rate, Biochemistry 37, 13835-13845.
19. Gulnik, S. V., Suvorov, L. I., Liu, B. S., Yu, B., Anderson, B., Mitsuya, H., and Erickson, J. W. (1995) Kinetic Characterization and Cross-Resistance Patterns of Hiv-1 Protease Mutants Selected under Drug Pressure, Biochemistry 34, 9282-9287.
20. Mahalingam, B., Boross, P., Wang, Y. F., Louis, J. M., Fischer, C. C., Tozser, J., Harrison, R. W., and Weber, I. T. (2002) Combining mutations in HIV-1 protease to understand mechanisms of resistance, Proteins 48, 107-116.
21. Shao, W., Everitt, L., Manchester, M., Loeb, D. D., Hutchison, C. A., and Swanstrom, R. (1997) Sequence requirements of the HIV-1 protease flap region determined by saturation mutagenesis and kinetic analysis of flap mutants, Proc. Natl. Acad. Sci. U.S.A. 94, 2243-2248.
22. Privalov, P. L., and Khechinashvili, N. N. (1974) A Thermodynamic Approach to the Problem of Stabilization of Globular Protein Structure: A Calorimetric Study, J. Mol. Biol. 86, 665-684.
23. Licalsi, C., Freire, E., and Roseman, S. (1991) Sugar Transport by the Bacterial Phosphotransferase System: Structural and Thermodynamic Domains of Enzyme I of Salmonella typhimurium, J. Biol. Chem. 266, 19519-19527.
24. Luque, I., Leavitt, S. A., and Freire, E. (2002) The linkage between protein folding and functional cooperativity: two sides of the same coin? Annu. Rev. Biophys. Biomol. Struct. 31, 235-256.
25. Alur, H. H., Desai, R. P., Mitra, A. K., and Johnston, T. P. (2001) Inhibition of a model protease: pyroglutamate aminopeptidase by natural oligosaccharide gum from Hakea gibbosa, Int. J. Pharm. 212, 171-176.
26. Ohtaka, H., Velazquez-Campoy, A., Xie, D., and Freire, E. (2002) Overcoming Drug Resistance in HIV-1 Chemotherapy: The Binding Thermodynamics of Amprenavir and TMC-126 to Wild-Type and Drug-Resistant Mutants of the HIV-1 Protease, Protein Sci. 11, 1908-1916.
27. Velazquez-Campoy, A., Todd, M. J., and Freire, E. (2000) HIV-1 Protease Inhibitors: Enthalpic versus Entropic Optimization of the Binding Affinity, Biochemistry 39, 2201-2207.
28. Velazquez-Campoy, A., Luque, I., Todd, M. J., Milutinovich, M., Kiso, Y., and Freire, E. (2000) Thermodynamic Dissection of the Binding Energetics of KNI-272, a Powerful HIV-1 Protease Inhibitor, Protein Sci. 9, 1801-1809.